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Birt-Hogg-Dube´ syndrome (BHD) is an autosomal-dominant genodermatosis characterized by skin fibrofolli-
culomas and an increased risk of spontaneous pneumothorax, renal and possibly other tumors. A causative
gene (FLCN) on chromosome 17p has recently been identified. We here report clinical and genetic studies of 20
BHD families ascertained by the presence of multiple fibrofolliculomas or trichodiscomas in the proband.
Pathogenic FLCN germline mutations were found in 11 (69%) of 16 probands tested and in 14 family members.
Six different FLCN germline mutations were detected, four of which have not been reported previously. The
clinical features were variable. None and less than 10 skin lesions were observed in two mutation carriers at the
age of 67 and 29 years, respectively. Spontaneous pneumothorax was reported in four and renal carcinoma of
mixed histological types in two of 36 BHD-affected individuals and/or FLCN mutation carriers. Both the
prevalence of spontaneous pneumothorax and renal tumors appeared to be relatively low compared with
previously reported data. Various other extracutaneous tumors were observed in 11 of 36 BHD-affected
individuals and/or FLCN mutation carriers. This study of the second largest cohort to date contributes to the
expanding data on the variable phenotype and underlying gene defects in BHD.
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INTRODUCTION
Birt-Hogg-Dube´ syndrome (BHD (OMIM #135150)) was first
described in 1977 by three Canadian physicians who studied
a family whose members were affected with multiple skin
fibrofolliculomas, trichodiscomas, and acrochordons on the
face, neck, and upper torso (Birt et al., 1977). The genetic
predisposition for this triad of cutaneous lesions became
known as BHD. The syndrome is now known to be an
autosomal-dominant genodermatosis of unknown incidence.
In addition to fibrofolliculomas, which tend to appear in the
third or fourth decade of life, affected individuals may have
pulmonary air filled cysts (Toro et al., 1999; Zbar et al.,
2002), spontaneous pneumothorax (Toro et al., 1999; Zbar
et al., 2002), and renal tumors (Roth et al., 1993; Toro et al.,
1999; Zbar et al., 2002). In a recent study, Zbar et al. (2002)
found that the odds ratios for developing spontaneous
pneumothorax and renal tumors in BHD-affected individuals
were 50.3 and 6.9, respectively. In the past, an association
between BHD and colorectal polyps and cancer was also
suggested (Rongioletti et al., 1989). However, recent studies
indicate that colorectal tumors are not associated with the
syndrome (Zbar et al., 2002) or, alternatively, occur only in a
small subset of families (Khoo et al., 2002).
In 2001, evidence for linkage of BHD on chromosome
17p11 was demonstrated (Khoo et al., 2001; Schmidt et al.,
2001). In 2002, the FLCN gene at this locus was identified
(Nickerson et al., 2002). The inactivating nature of the
majority of FLCN mutations reported to date (Khoo et al.,
2002; Nickerson et al., 2002; Schmidt et al., 2005; Van
Steensel et al., 2007), biallelic inactivation of FLCN in BHD-
associated renal tumors (Vocke et al., 2005) and animal
studies of BHD (Lingaas et al., 2003; Okimoto et al., 2004)
indicate a tumor-suppressor role of FLCN. A recent report
suggests that the corresponding protein folliculin (FLCN) and its
interacting partner FNIP1 may be involved in energy and/or
nutrient-sensing signaling pathways (Baba et al., 2006). Initial
reports on germline mutation analysis in BHD patients have
identified the poly (C) tract in exon 11 of the FLCN gene as a
mutational hotspot (Khoo et al., 2002; Nickerson et al., 2002),
but mutations located along the entire length of the coding
region of the gene have been identified (Schmidt et al., 2005).
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We here describe our observations of 20 BHD families,
ascertained by the department of dermatology at a university
hospital, a referral center for adnexal tumors of the skin.
Family studies and DNA mutation analysis were aimed at a
detailed evaluation of the clinical and genetic variability of
the syndrome.
RESULTS
The clinical and genetic features of BHD-affected individuals
and/or FLCN mutation carriers are summarized in Table 1.
Twenty clinically affected probands, ascertained from diffe-
rent regions in the Netherlands, were investigated. Family
studies revealed 12 clinically affected family members. The
mean age at clinical diagnosis was 43.3714.2 years
(mean7SD).
Germline mutation analysis was performed in 16 of the 20
probands. A pathogenic FLCN mutation was found in 11
(69%) of these 16 probands. The FLCN mutation found in the
proband was identified in a total of 14 family members, that
is, 10 clinically affected individuals, one individual without
any and one with less than 10 fibrofolliculomas or
trichodiscomas at the age of 67 and 29 years, respectively,
and two individuals who were not examined dermatologi-
cally. Six different pathogenic germline mutations (Figure 1)
were found, the majority of which are inactivating frameshift
and nonsense mutations. Only c.1740dupC, also referred to
as c.1733insC, and c.875delC have previously been reported
as germline mutations. The latter mutation has recently been
reported as 420delC by another Dutch group (Van Steensel
et al., 2007). Through personal communication we have
learnt that our patient IV-9 from family 3 and patient MB61
from the Van Steensel et al. (2007) study represent the same
subject. One additional frameshift mutation was found
in the remaining families. The nonsense mutation
c.1065_1066delGCinsTA (Figure 2) was detected in three
probands. The c.1074-1G4A and c.[1756-7del11; 1778del-
CinsGA] mutations that were detected both affect splice
acceptor sites.
Two probands had a history of spontaneous pneumo-
thorax. At the time of diagnosis, BHD was considered in
neither of these two patients. Family studies revealed two
additional cases of pneumothorax. In family 1, the two cases
were diagnosed at the age of 44 and 30 years, respectively.
One patient in family 14 experienced spontaneous pneumo-
thorax at the age of 36 years and the proband from family 18
had an unconfirmed case at the age of 22 years. None of the
four patients had bilateral or recurrent spontaneous pneu-
mothorax.
Two patients, both from family 6, had a history of renal
cell carcinoma (RCC). Through family studies we learnt that
subject III-23, the son of the proband, had been diagnosed
with a symptomatic unilateral focus of mixed papillary and
clear cell RCC at the age of 39 years. He died at the age of 40
years due to metastatic disease. Dermatological examination
was not performed, but the patient had no reported relevant
skin lesions. FLCN mutation analysis in histologically normal
tissue from tumor slides revealed that he was a carrier of the
mutation c.1740dupC, previously identified in his mother.
Independently, in another hospital, BHD was clinically
confirmed in subject III-30 from the same family after several
years of follow-up by the dermatologist. Subsequently, she
was referred for renal imaging and was diagnosed with an
occult unilateral bifocal RCC with elements of oncocytoma.
After surgery, she was referred for genetic counseling.
Mutation analysis revealed that she also carries the
c.1740dupC mutation.
Following genetic counseling, clinically affected patients
and/or FLCN mutation carriers were referred for renal tumor
screening by a combination of magnetic resonance imaging
investigation and baseline ultrasound. To date, no renal
tumors were detected in the baseline screening round in 21
subjects with a mean age of 48.0712.1 years. The first
annual follow-up screening round by renal ultrasound also
revealed no tumors.
Other tumors were reported in 11 clinically affected BHD
patients and/or FLCN mutation carriers: benign breast
disease, colorectal adenoma, oral fibroma, lipomas, inverted
papilloma of the nose, fibrosarcoma of the leg, skin basal cell
carcinoma, skin squamous cell carcinoma, human immuno-
deficiency virus-related B-cell non-Hodgkin lymphoma,
breast cancer, and an unconfirmed case of skin melanoma.
DISCUSSION
The clinical and genetic data of our 20 BHD families, the
second largest cohort to date, add in several ways to our
insight into the syndrome. Both the prevalence of renal
tumors and spontaneous pneumothorax appeared relatively
low compared with previously reported data. In the recent
study of BHD by Schmidt et al. (2005), renal tumors were
found in 38 (20%) of 187 affected individuals. Among the 36
clinically affected BHD patients and/or FLCN mutation
carriers in the 20 families we studied, 2 (6%) had a history
of RCC. As yet, screening of subjects did not reveal additional
renal tumors. In BHD, the histology of renal tumors is
unusual: various and/or mixed histological types are observed
not only within families but also in individual patients
(Pavlovich et al., 2002), which concurs with the histological
findings in our two RCC cases.
In the study by Schmidt et al. (2005), 64 (32%) of 198
BHD patients had a history of spontaneous pneumothorax. Of
the 129 BHD patients who were screened by pulmonary CT
scan, 110 (85%) were found to have one or more lung cysts
consistent with the BHD phenotype. We found spontaneous
pneumothorax in 4 (11%) of 36 clinically affected BHD
patients and/or FLCN mutation carriers. We did not system-
atically subject mutation carriers to CT scans of the lungs, as
there would be no direct medical consequences of the
demonstration of pulmonary cysts. Different ascertainment of
patients, different patient characteristics, environmental and/
or additional genetic factors may be the cause of the apparent
relatively low prevalence of renal tumors and spontaneous
pneumothorax in our study group. Because of these small
numbers possible genotype–phenotype correlations cannot
be speculated on.
Three families were diagnosed with trichodiscomas only.
The findings in these families are similar to those reported
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BHD1 III-10 m Td(58) 0 0 0 c.1065_1066delGCinsTA
(p.Ala204X)
III-11 f Ff(57) 0 0 0 c.1065_1066delGCinsTA
III-12 f Ff(49) 1 (44) 0 BBD(53) c.1065_1066delGCinsTA
IV-4 m Td(34) 1 (30) 0 0 c.1065_1066delGCinsTA
IV-9 f Ff(28) 0 0 Fs (14) c.1065_1066delGCinsTA
BHD2 III-3 m Ff(38) 0 0 0 No mutation detected
BHD3 III-6 f No Ff/Td(67) 0 0 0 c.875delC (p.Ile141fs)
IV-9 m Ff(40) 0 0 CrA(40) c.875delC
BHD4 III-1 m Ff(56) 0 0 BCC(54-64),SCC
(51-61),NHL(62)
c.1740dupC (p.His429fs)
BHD5 III-19 m Ff(33) 0 0 OF(34),L(31-36) No mutation detected
BHD6 II-9 f Ff(56) 0 0 IP(50),BCC(54/
70),BC(60)
c.1740dupC (p.His429fs)
III-23 m Uw(40) 0 1 (39) 0 c.1740dupC
III-25 f Td(40) 0 0 0 c.1740dupC
III-30 f Td(40) 0 1 (40) 0 c.1740dupC
BHD7 m Ff(62) DGC
BHD8 IV-5 f Ff(45) 0 0 BC(44) c.1110dupG (p.Ala219fs)
IV-6 f Ff(38) 0 0 0 c.1110dupG
BHD9 m Ff(34) 0 0 0 No mutation detected
BHD10 m Ff(55) DGC
BHD11 IV-3 f Td(38) 0 0 0 Not tested yet
BHD12 III-1 m Ff(46) 0 0 CrA(42/47/49) c.1740dupC (p.His429fs)
BHD13 m Ff(41) CrA(41) DGC
BHD14 II-6 m Ff(74) 0 0 0 c.1065_1066delGCinsTA
(p.Ala204X)
III-15 m Ff(44) 1 (36) 0 0 c.1065_1066delGCinsTA
III-17 m Ff(37) 0 0 0 c.1065_1066delGCinsTA
BHD15 III-1 m Ff(55) 0 0 0 c.1074-1G4A (SS)
IV-1 f o10 Ff(29) 0 0 0 c.1074-1G4A
II-7 f Uw(88) 0 0 CrA(83) c.1074-1G4A
BHD16 III-28 f Ff(57) 0 0 0 c.1065_1066delGCinsTA
(p.Ala204X)
III-29 f Ff(55) 0 0 0 c.1065_1066delGCinsTA
BHD17 III-6 m Td(34) 0 0 0 No mutation detected
IV-1 m Td(6) 0 0 0 Not tested
BHD18 III-12 m Ff(56) 1 (22) 0 M(38) c.[1756-7del11;
1778delCinsGA] (SS)
BHD19 III-7 m Ff(36) 0 0 0 c.1074-1G4A (SS)
BHD20 III-10 f Td(33) 0 0 0 No mutation detected
IV-6 m Td(10) 0 0 0 Not tested
BBD, benign breast disease; BC, breast cancer; BCC, basal cell cancer of the skin; CrA, colorectal adenoma; DGC, declined genetic counseling (i.e., family
studies and mutation analysis); f, female; Ff, fibrofolliculomas; Fs, fibrosarcoma of the leg; IP, inverted papilloma of the nose; L, lipomas; m, male;
M, melanoma; NHL, non-Hodgkin lymphoma of the stomach; OF, oral fibroma; Pneu, spontaneous pneumothorax; RCC, renal cell carcinoma; SCC,
squamous cell cancer of the skin; SS, splice-site mutation predicted to cause exon skipping; Td, trichodiscomas; U, unknown.
wDeceased (age at death in years).
Subjects in bold represent the proband. Mutation numbering according to GenBank sequence AF_517523.
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two decades ago by one of the authors (Starink et al., 1985) in
another family, which was not available for inclusion in this
study. FLCN mutations were identified in neither of our two
trichodiscoma-only families tested. The young age at clinical
diagnosis, 6 and 10 years respectively, in two subjects from the
two trichodiscoma-only families tested for FLCN mutations is
atypical for BHD. However, only one lesion was investigated
histologically in each family member and mutation analysis by
DNA sequencing was performed in one subject only from both
families. These families might represent a subtype of BHD or,
alternatively, a distinct syndrome.
The molecular analysis in this study has yielded several
novel FLCN germline mutations. The identification of mainly
inactivating frameshift and nonsense mutations in our study
group concurs with previous reports (Khoo et al., 2002;
Nickerson et al., 2002; Schmidt et al., 2005; Van Steensel
et al., 2007). In a recent update of molecular analysis,
Schmidt et al. (2005) found mutations in 51 (84%) of 61 BHD
families. More than half of all mutations consisted of an
insertion or deletion of a cytosine in a C8 tract within exon 11
of the gene, a mutational hotspot known from previous
studies (Khoo et al., 2002; Nickerson et al., 2002). We
identified six different germline FLCN mutations in 11 (69%)
of 16 probands tested of which 1740dupC, also referred to as
1733insC, has frequently been reported previously and
involves the hypermutable poly (C) tract in exon 11. Except
for c.875delC, none of the other germline mutations have
been reported previously. The c.875delC mutation has
previously been reported as a somatic mutation in a BHD-
associated renal tumor (Vocke et al., 2005) and as 420delC
by another Dutch group (Van Steensel et al., 2007) in a blood
sample, which they had received for research purposes from
the family 3 index patient. Two of the remaining mutations in
our study, c.1074-1G4A and c.[1756-7del11; 1778delCins-
GA], were intronic involving the splice acceptor site and are
predicted to cause exon skipping. Of note, referred to as
IVS6-1G4A, the former has previously been reported
as a somatic mutation in a BHD-associated renal tumor
(Vocke et al., 2005). In addition to 1740dupC, c.1074-1G4A
and c.1065_1066delGCinsTA were found in more than one
family and may represent founder mutations.
Among the patients we studied, several had undergone
colonoscopies due to the previously presumed association
with colorectal tumors (Rongioletti et al., 1989). Although
some small adenomatous polyps were found, we did not
observe colorectal cancer in our BHD families. In fact, the only
individual who has had bowel cancer was shown not to
be carrier of the FLCN mutation running in his family. Our
current data therefore do not suggest an increased risk for
colorectal tumors.
In conclusion, BHD should be suspected not only in
patients with the classical dermatological manifestations but
also in patients with few or even without fibrofolliculomas
and/or trichodiscomas who may present with (familial) renal
tumors and/or spontaneous pneumothorax. However, the
prevalence of renal tumors and spontaneous pneumothorax
in BHD families may vary due to yet unknown reasons.
Additional insight will be gained from future clinical and
molecular studies.
MATERIALS AND METHODS
Patients and clinical studies
Patients with BHD referred by the department of dermatology of the
VU University Medical Center in Amsterdam, The Netherlands, were
invited for family studies and FLCN germline mutation analysis. We
defined an individual as clinically affected with BHD when the
individual showed 10 or more skin lesions clinically compatible
with fibrofolliculomas or trichodiscomas (Figure 3) of which one was
histologically confirmed as such. Family studies were performed and
medical and histopathological data of patients and family members
were reviewed. Written informed consent was obtained from all
patients for all studies in accordance with institutional requirements
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Figure 1. Genomic structure of FLCN showing the location of the six
different germline mutations identified in 20 BHD families. In the coding
region of the gene (exons 4–14), three frameshift (F) and one nonsense (N)
mutation, all predicted to prematurely truncate the FLCN protein, were
detected. Two splice-site (SS) mutations predicted to cause exon skipping
were identified in introns 6 and 11.
Figure 2. A novel FLCN germline mutation found in three BHD families.
FLCN sequence showing the (a) wild-type and (b) c.1065_1066delGCinsTA
allele.
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Mutation analysis
Genomic DNA was extracted from blood samples. Histologically
normal tissue from a renal carcinoma slide of a deceased member of
family 6 was also included for DNA extraction. Primers for the
amplification and sequencing of the 14 exons were as detailed by
Nickerson et al. (2002). Amplification by PCR was performed using a
PE 9700 thermocycler (Applied Biosystems, Forster City, CA).
Sequencing reactions were performed using Big Dye Terminator
(Applied Biosystems) and run on an ABI 3100 genetic analyzer
(Applied Biosystems).
Imaging studies
Following genetic counseling, clinically affected patients and/or
FLCN mutation carriers were referred for renal tumor screening by a
combination of magnetic resonance imaging investigation (Siemens
Sonata 1.5 T) and baseline ultrasound (Siemens Acuson Sequoia 512)
starting at the age of 25 years. The magnetic resonance imaging scan
was carried out with the fast imaging technique (TrueFisp), T1 and
T2 pulse sequences and T2 Haste with prospective acquisition
correction (PACE) in order to readily distinguish solid from small
cystic lesions. Intravenous gadolinium diethylenetriamine penta-
acetic acid (DTPA) was administered when necessary. Annual follow-up
was performed by renal ultrasound.
No imaging studies were performed to evaluate the presence of
lung cysts.
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Figure 3. Skin manifestations in four BHD patients. Multiple small
skin-colored papules clinically compatible with fibrofolliculomas or
trichodiscomas (a) in the neck area and (b) on the ear of patient III-12 from
family 1, (c) on the forehead of patient III-3 from family 2, and (d) on the nose
and paranasal area of patient IV-6 from family 8. (e) Biopsy of one of the
papules of the proband from family 13 shows the characteristic histological
picture of a fibrofolliculoma. The hair follicle is dilated, its basal layer forms
fine anastomosing strands of basaloid cells and is surrounded by a sharply
demarcated layer of fibromucinous stroma. Bar¼250 mm.
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